Clarus Therapeutics Holdings Receivables

Clarus Therapeutics Holdings (CRXT) currently reports a receivables of $8.7M as of June 2022. That compares with $6.2M in the prior-year period — up 39.7% year over year. Use the charts on this page to explore Clarus Therapeutics Holdings's receivables history and peer comparisons.

Clarus Therapeutics Holdings's receivables increased from $6.2M to $8.7M — a 39.7% year-over-year increase (period ending June 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Clarus Therapeutics Holdings reported $8.7M in receivables as of June 2022. That compares with $6.2M in the prior-year period — up 39.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $8.7M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Clarus Therapeutics Holdings, and consider following CRXT for alerts when major investors trade the stock.